ILK and breast carcinoma: After treatment with doxorubicin on substrates of 10, 38 and 57 kPa in MDA-MB-231 cells, cell viability was much higher on stiffer substrates and inhibition of Integrin-Linked Kinase (ILK) abolished the effect of matrix stiffness on drug response, suggesting that matrix stiffness affected the process of the sensitivity of chemotherapy via ILK in breast cancer cells [89].